Back to top
more

Anavex Life Sciences (AVXL)

(Delayed Data from NSDQ)

$6.50 USD

6.50
1,262,362

-0.09 (-1.29%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $6.50 +0.01 (0.08%) 7:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Anavex's (AVXL) Lead Alzheimer's Drug Meets Study Goal

by Zacks Equity Research

Top-line data from a phase IIb/III study shows that Anave's (AVXL) lead drug exhibited statistical and clinical improvement in cognition and function in patients with early Alzheimer's disease.

Wall Street Analysts Think Anavex Life Sciences (AVXL) Could Surge 179%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 179.5% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Why Endo (ENDP) Stock Wilted After its Surge on Tuesday?

by Zacks Equity Research

Endo International (ENDO) tanks 26%, cooling off after its massive stock price surge on Tuesday, post the Supreme Court's decision to overturn Roe v. Wade.

Global Blood (GBT) Initiates Phase II Study on SCD Candidate

by Zacks Equity Research

Global Blood Therapeutics (GBT) initiates the phase II portion of its planned phase II/III studies on pipeline candidate GBT601 to identify the optimal dose for the pivotal phase III portion of the trial

BioMarin (BMRN) Gets CHMP Nod for Hemophilia Drug Roctavian

by Zacks Equity Research

BioMarin (BMRN) receives a positive CHMP opinion for Roctavian, its gene therapy for treating adults with hemophilia A. The European Commission's decision is expected by the third quarter of 2022.

Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 238%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 238.3% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Celldex (CLDX) Initiates Phase II Chronic Skin Disorder Study

by Zacks Equity Research

Celldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate, barzolvolimab, for treating patients with chronic spontaneous urticaria.

Rhythm Pharma (RYTM) Down on Mixed Imcivree Regulatory Updates

by Zacks Equity Research

The FDA approves label expansion of Rhythm Pharma's (RYTM) Imcivree to include Bardet-Biedl Syndrome patients. However, the FDA provides CRL for label expansion of the drug in Alstrom syndrome.

How Much Upside is Left in Anavex Life Sciences (AVXL)? Wall Street Analysts Think 286%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 286.4% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Immunovant (IMVT) Sees Wider Q4 Loss, to Study Batoclimab in TED

by Zacks Equity Research

Immunovant's (IMVT) earnings miss estimates in fiscal fourth quarter ended on Mar 31, 2022. The company achieves FDA alignment for phase III study on batoclimab in thyroid eye disease.

Apellis (APLS), Sobi Begin Pegcetacoplan Dosing in Kidney Disease

by Zacks Equity Research

Apellis (APLS) and Sobi dose the first patient in phase III VALIANT study evaluating pegcetacoplan in primary immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy. Stock up.

Praxis (PRAX) Tanks on Negative Data From Depression Study

by Zacks Equity Research

Praxis (PRAX) posts negative data from the phase II/III Aria study that evaluated PRAX-114 for monotherapy treatment of major depressive disorder. Shares fall.

GSK Gets FDA Nod for Measles, Mumps & Rubella Vaccine, Priorix

by Zacks Equity Research

The FDA approves GSK's Priorix vaccine for active immunization for the prevention of measles, mumps and rubella in individuals aged 12 months and older.

Immunocore (IMCR) Up on Deal With Sanofi for Skin Cancer Study

by Zacks Equity Research

Immunocore (IMCR) signs a collaboration agreement with Sanofi to study the combination of Kimmtrak with the latter's SAR444245 for treating metastatic cutaneous melanoma. Shares up.

Immunic (IMUX) Falls as Phase II Ulcerative Colitis Study Fails

by Zacks Equity Research

Immunic's (IMUX) phase II CALDOSE-1 study, evaluating vidofludimus calcium in patients with moderate-to-severe ulcerative colitis, fails to meet primary endpoint. Stock down.

Aeglea (AGLE) Down on RTF Letter from FDA for Rare Disease Drug

by Zacks Equity Research

Aeglea (AGLE) gets a Refusal to File letter from the FDA related to the biologics license application for pegzilarginase to treat arginase 1 deficiency. Stock down.

Does Anavex Life Sciences (AVXL) Have the Potential to Rally 265% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 265% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is the Options Market Predicting a Spike in Anavex (AVXL) Stock?

by Zacks Equity Research

Investors need to pay close attention to Anavex (AVXL) stock based on the movements in the options market lately.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XBI

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Anavex (AVXL) to Report Q3 Earning: What's in the Cards?

by Zacks Equity Research

On Anavex's (AVXL) earnings call for the fiscal third quarter, investor focus will mainly be on the company's progress with its lead investigational candidate for Alzheimer's disease.

Company News for Jun 29, 2021

by Zacks Equity Research

Companies in the news are: NTLA, AVXL, MNKD, KYMR

Biotech Stock Roundup: BIIB's AD Drug Update, CVAC's Decline on Vaccine Data & More

by Zacks Equity Research

The biotech sector was in focus last week with pipeline updates from Biogen (BIIB) and CureVac (CVAC), among others.

Implied Volatility Surging for Anavex Life Sciences (AVXL) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Anavex Life Sciences (AVXL) stock based on the movements in the options market lately.

Company News for Jun 15, 2021

by Zacks Equity Research

Companies In The News Are: RIDE, PHG, AVXL, RDS.A